We assessed the safety, and postoperative urinary status of holmium laser enucleation of the prostate (HoLEP) for the treatment of benign prostatic hyperplasia (BPH).
Of the initial 117 patients who underwent HoLEP from November 2004 to March 2011, 49 were followed up for two years or longer. These 49 patients were evaluated once preoperatively, and at the 3rd, 6th, 12th, 24th, 48th, and 60th month postoperatively using International Prostate Symptom Scores (I-PSS) total and sub-score, quality of life score (QOL), maximum flow rate (Qmax), and post-voiding residual urine volume (PVR). The median estimated transition zone and enucleated volume were 45. 1 and 47. 9 g, respectively. Evaluation scores showed significant improvements throughout the follow-up. I-PSS total scores improved from 21 points(before surgery) to 6 points(12 months after surgery), QOL scores improved from 5 points to 2 points, Qmax improved from 6.8 ml/s to 17.4 ml/s, and PVR improved from 101 ml to 26 ml, respectively. Transient urinary incontinence was noted in 14 patients (28.5%). One case showed a Clavien grade 3 complication of postoperative bleeding. No blood transfusion or re-surgery for BPH was required. In conclusion, HoLEP proved to be a safe and effective therapy, with potential to become a new gold standard for treating BPH.
Written by:
Kono Y, Matsumoto K, Masuda N, Shiraishi Y, Negoro H, Utsunomiya N, Tsunemori H, Okubo K, Okada T, Segawa T, Muguruma K, Kawakita M. Are you the author?
The Department of Urology, Kobe City Medical Center General Hospital.
Reference: Hinyokika Kiyo. 2014 Feb;60(2):57-60.
PubMed Abstract
PMID: 24755814
Article in Japanese.
